OKYO Pharma Statistics
Total Valuation
OKYO Pharma has a market cap or net worth of $80.82 million. The enterprise value is $54.98 million.
| Market Cap | 80.82M |
| Enterprise Value | 54.98M |
Important Dates
The last earnings date was Monday, July 20, 2026, before market open.
| Earnings Date | Jul 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OKYO Pharma has 52.48 million shares outstanding. The number of shares has decreased by -5.40% in one year.
| Current Share Class | 52.48M |
| Shares Outstanding | 52.48M |
| Shares Change (YoY) | -5.40% |
| Shares Change (QoQ) | -0.34% |
| Owned by Insiders (%) | 31.88% |
| Owned by Institutions (%) | 12.96% |
| Float | 28.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.13 |
| P/TBV Ratio | 6.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.43
| Current Ratio | 2.43 |
| Quick Ratio | 2.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.93 |
Financial Efficiency
Return on equity (ROE) is -263.78% and return on invested capital (ROIC) is -156.57%.
| Return on Equity (ROE) | -263.78% |
| Return on Assets (ROA) | -43.09% |
| Return on Invested Capital (ROIC) | -156.57% |
| Return on Capital Employed (ROCE) | -68.91% |
| Weighted Average Cost of Capital (WACC) | 4.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.24M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, OKYO Pharma has paid $7,987 in taxes.
| Income Tax | 7,987 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.87% in the last 52 weeks. The beta is 0.05, so OKYO Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.05 |
| 52-Week Price Change | -47.87% |
| 50-Day Moving Average | 1.58 |
| 200-Day Moving Average | 1.88 |
| Relative Strength Index (RSI) | 44.97 |
| Average Volume (20 Days) | 154,634 |
Short Selling Information
The latest short interest is 32,380, so 0.06% of the outstanding shares have been sold short.
| Short Interest | 32,380 |
| Short Previous Month | 82,735 |
| Short % of Shares Out | 0.06% |
| Short % of Float | 0.12% |
| Short Ratio (days to cover) | 0.51 |
Income Statement
| Revenue | n/a |
| Gross Profit | -6.69M |
| Operating Income | -8.50M |
| Pretax Income | -8.94M |
| Net Income | -8.95M |
| EBITDA | -8.50M |
| EBIT | -8.50M |
| Earnings Per Share (EPS) | -$0.24 |
Balance Sheet
The company has $20.59 million in cash and n/a in debt, with a net cash position of $20.59 million or $0.39 per share.
| Cash & Cash Equivalents | 20.59M |
| Total Debt | n/a |
| Net Cash | 20.59M |
| Net Cash Per Share | $0.39 |
| Equity (Book Value) | 12.34M |
| Book Value Per Share | 0.24 |
| Working Capital | 12.33M |
Cash Flow
In the last 12 months, operating cash flow was -$5.94 million and capital expenditures -$6,080, giving a free cash flow of -$5.94 million.
| Operating Cash Flow | -5.94M |
| Capital Expenditures | -6,080 |
| Depreciation & Amortization | 1,820 |
| Net Borrowing | n/a |
| Free Cash Flow | -5.94M |
| FCF Per Share | -$0.11 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OKYO Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 5.40% |
| Shareholder Yield | 5.40% |
| Earnings Yield | -11.84% |
| FCF Yield | -7.86% |
Analyst Forecast
The average price target for OKYO Pharma is $8.33, which is 440.91% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.33 |
| Price Target Difference | 440.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 22, 2023. It was a reverse split with a ratio of 1:65.
| Last Split Date | May 22, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:65 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |